Kianna Finley, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 26 Round Butte Rd, Ronan, MT 59864 Phone: 406-745-3525 Fax: 406-745-4721 |
Mrs. Vanessa Anne Courville, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 28 Round Butte Rd, Ronan, MT 59864 Phone: 406-676-8778 Fax: 406-676-0132 |
Morgan Malatare, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 35840 Round Butte Rd, Ronan, MT 59864 Phone: 406-745-3525 Fax: 406-745-4721 |
Kristin A. Murphy, R.N. Registered Nurse - Community Health Medicare: Not Enrolled in Medicare Practice Location: 35860 Round Butte Rd., Ronan, MT 59864 Phone: 406-745-3525 Fax: 406-745-3529 |
Toni Michel, Registered Nurse - Community Health Medicare: Not Enrolled in Medicare Practice Location: 30 Round Butte Rd W, Ronan, MT 59864 Phone: 406-676-0137 |
Sarah A.s. Meeks, DNP, FNP-C Registered Nurse - Community Health Medicare: Medicare Enrolled Practice Location: 430 Mary Mcleod Ln, Ronan, MT 59864 Phone: 406-745-3525 |
Barbara J Plouffe, RN CHN Registered Nurse - Community Health Medicare: Not Enrolled in Medicare Practice Location: 35866 Round Butte Road, Ronan, MT 59864 Phone: 406-676-0137 Fax: 406-676-0134 |
Chris Westphal, RNFA Registered Nurse - Registered Nurse First Assistant Medicare: Not Enrolled in Medicare Practice Location: 126 6th Ave Sw Ste B, Ronan, MT 59864 Phone: 406-676-4436 Fax: 406-676-4430 |
News Archive
AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.
Antibiotics shouldn't be given to children as a preventative measure to try to avoid another urinary tract infection for kids who have already had one infection, as it's unlikely to prevent another UTI and also contributes to the growing problem of antibiotic resistance.
Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the tentative scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the company's supplemental New Drug Application (sNDA) for VIVITROL® (naltrexone for extended-release injectable suspension) for opioid dependence.
NPR reports that not much has changed in the new regulation other than requiring coverage for contraceptives at no cost, while CNN reports on the escalating "rhetorical war" in Washington.
› Verified 2 days ago